Endowed Chair in Esophageal Cancer Established

When Katy Rady lost her brother, Paul R. O’Hara II to cancer, she turned her…

Read the rest of this entry

CU Cancer Center chemoprevention trial hopes to stop lung cancer before it starts

Ongoing clinical trial by University of Colorado Cancer Center investigators is evaluating the ability of an inhaled form of the pulmonary hypertension drug iloprost to prevent lung cancer.

Read the rest of this entry

‘Overturning established fact’ leads to new understanding, new target in MLL-rearranged leukemia

“This basic science has the real potential to affect the development of future drugs that could improve the lives of patients with these conditions,” says Patricia Ernst, PhD.

Read the rest of this entry

Metastatic breast cancer cells use hedgehog to ‘evilize’ docile neighbors

CU Cancer Center study pinpoints promising link in the chain of hedgehog signaling that, when broken, could reduce the metastatic potential of breast cancer.

Read the rest of this entry

Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer

Overall survival was median 5.9 months for the two-drug combination and 9.6 months with the addition of vemurafenib.

Read the rest of this entry

Study evaluates overall geriatric health during androgen deprivation therapy

CU Cancer Center study evaluates the effects of androgen deprivation therapy not just on patients’ physical function but on global geriatric health, including skills of daily living.

Read the rest of this entry

CONNECT registry shows only 9 percent compliance with genetic testing guidelines for AML

CU Cancer Center study presented at ASCO 2017 shows that of 259 AML patients, only 9 percent received recommended genetic testing.

Read the rest of this entry

Dasatinib excels in worldwide phase II trial against pediatric CML

Worldwide phase II clinical trial results presented at ASCO 2017 show the promise of the second-generation drug dasatinib against pediatric CML. Of 113 pediatric patients studied, 75 percent of patients who had previously failed or did not tolerate imatinib saw progression-free survival 48 months after starting treatment with dasatinib.

Read the rest of this entry

First-line use of Alectinib potential new standard of care for ALK-positive non-small cell lung cancer

Results of a 303-patient, multi-national phase III clinical trial known as ALEX published today in NEJM and presented concurrently at ASCO 2017 argue for alectinib replacing crizotinib as first-line standard of care in advanced ALK-positive non-small cell lung cancer.

Read the rest of this entry

Smartphone app evaluation presented at American Society for Clinical Oncology Annual Meeting

As cancer science evolves, so too does cancer treatment. More and more patients are able…

Read the rest of this entry